Selvita SA (SLV):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Selvita SA (SLV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8158)・商品コード:DATA904C8158
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Selvita SA (Selvita) is a drug discovery company that focuses on the research and development of cancer therapies. The company develops novel small molecule drugs, and markets them with partners from the pharmaceutical industry. Its products find application in the therapeutic areas of oncology, inflammation, leukemia, lymphoma, solid tumors and hematological malignancies. Selvita also offers services such as contract chemistry services, biology services, drug discovery services, computational chemistry, medicinal chemistry, analytical services, preclinical research, and quality assurance services. The company caters to pharmaceutical and biotechnology companies. It has presence in Poland, the US and the UK. Selvita is headquartered in Krakow, Poland.

Selvita SA (SLV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Selvita SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Selvita SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Selvita SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Selvita Enters into Agreement with Leukemia & Lymphoma Society 10
Selvita Enters into Agreement with Nodthera 11
Selvita Enters into Agreement with University of California, San Francisco 12
Selvita Enters into Agreement with Merck 13
Selvita Enters into Development and Commercialization Agreement with Merck 14
Felicitex Therapeutics Enters into Co-Development Agreement with Selvita 15
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 16
H3 Biomedicine Extends Agreement with Selvita 17
Licensing Agreements 18
Berlin-Chemie Enters into Licensing Agreement with Selvita 18
Merck Enters into Licensing Agreement with Selvita 19
Equity Offering 20
Selvita Raises USD40.3 Million in Public Offering of Shares 20
Selvita Raises USD0.1 Million in Private Placement of Shares 21
Selvita Raises USD8 Million in IPO 22
Selvita SA – Key Competitors 24
Selvita SA – Key Employees 25
Selvita SA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Sep 11, 2018: Selvita announces H1 2018 financial results 27
May 25, 2018: Selvita reports strong business growth in Q1 2018 28
Apr 04, 2018: Selvita shows a very strong, 60% business growth in 2017 29
Sep 15, 2017: Selvita Demonstrates Strong Revenue Growth in H1 2017 30
May 31, 2017: Selvita doubles the revenue in Q1 2017 vs. Q1 2016 31
Apr 20, 2017: Selvita Shows 19% Business Growth in 2016 32
Corporate Communications 33
Feb 06, 2018: Selvita Appoints Steffen Heeger, M.D., PhD as Chief Medical Officer 33
Product News 34
Feb 13, 2017: Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Selvita SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Selvita SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Selvita SA, Deals By Therapy Area, 2012 to YTD 2018 8
Selvita SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Selvita Enters into Agreement with Leukemia & Lymphoma Society 10
Selvita Enters into Agreement with Nodthera 11
Selvita Enters into Agreement with University of California, San Francisco 12
Selvita Enters into Agreement with Merck 13
Selvita Enters into Development and Commercialization Agreement with Merck 14
Felicitex Therapeutics Enters into Co-Development Agreement with Selvita 15
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 16
H3 Biomedicine Extends Agreement with Selvita 17
Berlin-Chemie Enters into Licensing Agreement with Selvita 18
Merck Enters into Licensing Agreement with Selvita 19
Selvita Raises USD40.3 Million in Public Offering of Shares 20
Selvita Raises USD0.1 Million in Private Placement of Shares 21
Selvita Raises USD8 Million in IPO 22
Selvita SA, Key Competitors 24
Selvita SA, Key Employees 25
Selvita SA, Other Locations 26
Selvita SA, Subsidiaries 26

List of Figures
Selvita SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Selvita SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Selvita SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Selvita SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Selvita SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Selvita SA (SLV):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8158)販売に関する免責事項を必ずご確認ください。
★調査レポート[Selvita SA (SLV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆